Table 5.
Results of GLMs to assess the effects of patient characteristics on the total cost of AEs
| Covariates | Coefficients | Estimates (USD) | p-value | 95% confidence intervals (USD) | |
|---|---|---|---|---|---|
| GLM 1 | |||||
| Adverse events (0 = absent, 1 = present) | 0.467 | $3,750.06 | 0.013a | $802.89 | $6,697.22 |
| Sex (0 = male, 1 = female) | 0.160 | $1,289.68 | 0.263a | -$966.69 | $3,546.06 |
| Age (years) | 0.002 | $12.95 | 0.938a | -$313.52 | $339.43 |
| Risk of neoplastic relapse (0 = standard, 1 = high) | 0.302 | $2,430.59 | 0.043a | $80.94 | $4,780.24 |
| Time to get ALL remission (days) | 0.041 | $330.50 | 0.004a | $105.31 | $555.69 |
| Hospitalization (0 = no, 1 = yes) | 0.448 | $3,601.37 | 0.002a | $1,302.69 | $5,900.04 |
| Deaths | 0.780 | $6,273.87 | 0.028a | $693.88 | $11,853.87 |
| Intercept | 6.859 | 0.000a | |||
| GLM 2 | |||||
| Adverse events (count predictor) | 0.072 | $564.64 | 0.002a | $202.07 | $927.22 |
| Sex (0 = male, 1 = female) | 0.042 | $330.42 | 0.717a | -$1,453.15 | $2,113.99 |
| Age (years) | 0.005 | $40.83 | 0.746a | -$206.29 | $287.95 |
| Risk of neoplastic relapse (0 = standard, 1 = high) | 0.259 | $2,020.45 | 0.048a | $18.96 | $4,021.94 |
| Hospitalization (0 = no, 1 = yes) | 0.303 | $2,364.41 | 0.028a | $250.26 | $4,478.56 |
| Time to get ALL remission (days) | 0.029 | $226.73 | 0.002a | $80.36 | $373.11 |
| Deaths | -0.169 | -$1,320.33 | 0.656a | -$7,125.56 | $4,484.90 |
| Intercept | 7.383 | 0.000a | |||
GLM Generalized linear models, USD United States Dollar
aWilcoxon rank sum test